Sanyuan Biotechnology announced that shareholder Luxin Capital's reduction plan has expired. It originally planned to reduce its holdings by no more than 6 million shares, or no more than 3% of the total share capital after excluding shares in the repurchase special account, starting from a specific time in 2025, through centralized bidding and block trading. As of the announcement date, Luxin Capital reduced its holdings by 4 million shares through block trading and 1.99005 million shares through centralized bidding from August 7 to October 29, 2025, totaling 5.99005 million shares, accounting for 2.995%. After the reduction, Luxin Capital's holdings decreased to 1.93 million shares, accounting for 0.97% of the total share capital. This reduction did not lead to a change in the company's control and had no significant impact on the company's operations
